Impact of montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19): protocol for an investigator-initiated open labeled randomized controlled pragmatic trial.
Covid-19
SARS-CoV-2
coronavirus
montelukast
randomized controlled trial
treatment
Journal
Porto biomedical journal
ISSN: 2444-8672
Titre abrégé: Porto Biomed J
Pays: United States
ID NLM: 101707479
Informations de publication
Date de publication:
Historique:
received:
23
01
2021
revised:
04
02
2021
accepted:
05
02
2021
entrez:
19
4
2021
pubmed:
20
4
2021
medline:
20
4
2021
Statut:
epublish
Résumé
Montelukast, a safe drug widely use in asthmatic patients, may be an adjuvant in the treatment of Covid-19, either by improving lung injury and inflammation, or by acting as an anti-viral drug. We aim to assess the efficacy and safety of montelukast as add-on treatment in patients with Covid-19. We propose a randomized, controlled, parallel, open-label trial involving 160 hospitalized adult patients with confirmed Covid-19. Patients will be randomly assigned in a 1:1 ratio to receive either montelukast 10 mg, once a day for 14 days, in addition to standard of care (SoC), or SoC alone. SoC will follow the best practice for treating these patients, according to updated recommendations. The primary outcome is time to recovery. Participants will be assessed using diary cards to capture data on treatment-related improvements in an 8-point ordinal scale. Secondary endpoints will include changes in respiratory and inflammatory parameters, and adverse events. This phase IV clinical trial will take place at the University Hospital of São João, Porto. EudraCT number: 2020-001747-21. This study intends to generate scientific evidence on efficacy and safety of montelukast as add-on treatment in Covid-19. The results will be essential to improve clinical outcomes which remains to be determined. Montelukast has been suggested as a potential drug with 2 main actions on Covid-19. The validation of montelukast as an adjuvant treatment may improve lung injury, inflammation, and symptoms leading to a better prognosis. The use of this drug may fulfil the existing gap on therapeutic options.
Sections du résumé
BACKGROUND
BACKGROUND
Montelukast, a safe drug widely use in asthmatic patients, may be an adjuvant in the treatment of Covid-19, either by improving lung injury and inflammation, or by acting as an anti-viral drug. We aim to assess the efficacy and safety of montelukast as add-on treatment in patients with Covid-19.
METHODS
METHODS
We propose a randomized, controlled, parallel, open-label trial involving 160 hospitalized adult patients with confirmed Covid-19. Patients will be randomly assigned in a 1:1 ratio to receive either montelukast 10 mg, once a day for 14 days, in addition to standard of care (SoC), or SoC alone. SoC will follow the best practice for treating these patients, according to updated recommendations. The primary outcome is time to recovery. Participants will be assessed using diary cards to capture data on treatment-related improvements in an 8-point ordinal scale. Secondary endpoints will include changes in respiratory and inflammatory parameters, and adverse events. This phase IV clinical trial will take place at the University Hospital of São João, Porto. EudraCT number: 2020-001747-21.
RESULTS
RESULTS
This study intends to generate scientific evidence on efficacy and safety of montelukast as add-on treatment in Covid-19. The results will be essential to improve clinical outcomes which remains to be determined.
CONCLUSION
CONCLUSIONS
Montelukast has been suggested as a potential drug with 2 main actions on Covid-19. The validation of montelukast as an adjuvant treatment may improve lung injury, inflammation, and symptoms leading to a better prognosis. The use of this drug may fulfil the existing gap on therapeutic options.
Identifiants
pubmed: 33869886
doi: 10.1097/j.pbj.0000000000000134
pii: PBJ-D-21-00004
pmc: PMC8049153
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e134Informations de copyright
Copyright © 2021 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of PBJ-Associação Porto Biomedical/Porto Biomedical Society. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Resuscitation. 2013 Apr;84(4):465-70
pubmed: 23295778
Emerg Microbes Infect. 2020 Dec;9(1):221-236
pubmed: 31987001
Chem Biol. 2004 Oct;11(10):1445-53
pubmed: 15489171
Chin Med J (Engl). 2020 May 5;133(9):1015-1024
pubmed: 32004165
Pediatr Pulmonol. 2009 Jun;44(6):568-79
pubmed: 19449366
BMJ. 2020 Jan 31;368:m406
pubmed: 32005675
Sci China Life Sci. 2020 Mar;63(3):364-374
pubmed: 32048163
Nat Med. 2005 Aug;11(8):875-9
pubmed: 16007097
Allergol Int. 2017 Sep;66S:S21-S26
pubmed: 28647381
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Acta Pharm Sin B. 2020 May;10(5):766-788
pubmed: 32292689
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Science. 2003 Jun 13;300(5626):1763-7
pubmed: 12746549
J Pharm Anal. 2020 Aug;10(4):313-319
pubmed: 32296570
Blood. 2005 Oct 1;106(7):2366-74
pubmed: 15860669
J Lung Pulm Respir Res. 2018;5(1):
pubmed: 30175235
Turk Gogus Kalp Damar Cerrahisi Derg. 2018 Sep 16;26(4):588-597
pubmed: 32082801
J Allergy Clin Immunol. 2007 Mar;119(3):618-25
pubmed: 17336611
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651